What is CRVS's current stock price?

CRVS (Corvus Pharmaceuticals, Inc.) is currently trading at $12.61 with a market cap of $1.06B.

What sector is Corvus Pharmaceuticals, Inc. in?

Corvus Pharmaceuticals, Inc. (CRVS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CRVS a good stock to buy?

Analysts have a Buy consensus on CRVS with a price target of $33.17. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CRVS Corvus Pharmaceuticals, Inc.

Healthcare

$12.61-3.59%ClosedMarket Cap: $1.06B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.72

P/S

0.00

EV/EBITDA

-21.53

DCF Value

$0.02

FCF Yield

-3.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-38.9%

ROA

-17.4%

ROIC

-19.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-13.7M	$—
Q4 null	$0.00	$-12.3M	$—
FY null	$0.00	$-15.3M	$—
Q3 null	$0.00	$-10.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$33.17

Target (Median)

$31.00

Target Range

$27.00 - $42.00

1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

OppenheimerOutperform

2026-03-13

JefferiesBuy

2026-01-22

BarclaysOverweight

2026-01-21

OppenheimerOutperform

2026-01-21

HC Wainwright & Co.Buy

2026-01-20

Trading Activity

Insider Trades

View All

MILLER RICHARD A MDdirector, officer: President and CEO

BuyWed May 20

MILLER RICHARD A MDdirector, officer: President and CEO

BuyWed May 20

Chan Andrew C.director

SellMon Apr 27

Chan Andrew C.

SellMon Apr 27

Thompson Peter A.director, 10 percent owner:

SellFri Jan 30

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.94

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Peers